Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.

Montes de Jesus FM, Kwee TC, Kahle XU, Nijland M, van Meerten T, Huls G, Dierckx RAJO, Rosati S, Diepstra A, van der Bij W, Verschuuren EAM, Glaudemans AWJM, Noordzij W.

Eur J Nucl Med Mol Imaging. 2019 Aug 24. doi: 10.1007/s00259-019-04481-7. [Epub ahead of print]

PMID:
31444510
2.

CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.

Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T.

Cancer Immunol Res. 2019 Aug 13. doi: 10.1158/2326-6066.CIR-18-0781. [Epub ahead of print]

PMID:
31409608
3.

Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma.

Kahle XU, Montes de Jesus FM, Kwee TC, van Meerten T, Diepstra A, Rosati S, Glaudemans AWJM, Noordzij W, Plattel WJ, Nijland M.

Sci Rep. 2019 Jul 30;9(1):11073. doi: 10.1038/s41598-019-47453-5.

4.

Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

Bouwstra R, van Meerten T, Bremer E.

Mol Cell Oncol. 2019 Apr 16;6(3):1600349. doi: 10.1080/23723556.2019.1600349. eCollection 2019.

PMID:
31131314
5.

Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements.

Kahle XU, Hovingh M, Noordzij W, Seitz A, Diepstra A, Visser L, van den Berg A, van Meerten T, Huls G, Boellaard R, Kwee TC, Nijland M.

Eur Radiol. 2019 Apr 26. doi: 10.1007/s00330-019-06178-9. [Epub ahead of print]

PMID:
31028445
6.

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.

He Y, Bouwstra R, Wiersma VR, de Jong M, Jan Lourens H, Fehrmann R, de Bruyn M, Ammatuna E, Huls G, van Meerten T, Bremer E.

Nat Commun. 2019 Feb 1;10(1):533. doi: 10.1038/s41467-018-08013-z.

7.

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.

Nijland M, Seitz A, Terpstra M, van Imhoff GW, Kluin PM, van Meerten T, Atayar Ç, van Kempen LC, Diepstra A, Kok K, van den Berg A.

Cancers (Basel). 2018 Nov 20;10(11). pii: E459. doi: 10.3390/cancers10110459.

8.

Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.

Montes de Jesus FM, Kwee TC, Nijland M, Kahle XU, Huls G, Dierckx RAJO, van Meerten T, Gheysens O, Dierickx D, Vergote V, Noordzij W, Glaudemans AWJM.

Crit Rev Oncol Hematol. 2018 Dec;132:27-38. doi: 10.1016/j.critrevonc.2018.09.007. Epub 2018 Sep 19.

9.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting.

van der Galiën HT, Hoogendoorn M, Kibbelaar RE, van Meerten T, van Rijn RS.

Ann Oncol. 2019 Jan 1;30(1):151-152. doi: 10.1093/annonc/mdy482. No abstract available.

PMID:
30364941
10.

Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.

Alkhawtani RHM, Noordzij W, Glaudemans AWJM, van Rijn RS, van der Galiën HT, Balink H, Nijland M, Adams HJA, Huls G, van Meerten T, Kwee TC.

Nucl Med Commun. 2018 Jun;39(6):572-578. doi: 10.1097/MNM.0000000000000840.

PMID:
29672465
11.

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.

de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt M, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN, van Meerten T.

PLoS One. 2018 Feb 28;13(2):e0193098. doi: 10.1371/journal.pone.0193098. eCollection 2018.

12.

Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma.

Nijland M, van Meerten T, Seitz A, Huls G, Kibbelaar R, Visser L, van den Berg A, Diepstra A.

Ann Hematol. 2018 May;97(5):905-907. doi: 10.1007/s00277-018-3233-9. Epub 2018 Jan 11. No abstract available.

PMID:
29327077
13.

CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.

van Bommel PE, He Y, Schepel I, Hendriks MAJM, Wiersma VR, van Ginkel RJ, van Meerten T, Ammatuna E, Huls G, Samplonius DF, Helfrich W, Bremer E.

Oncoimmunology. 2017 Oct 31;7(2):e1386361. doi: 10.1080/2162402X.2017.1386361. eCollection 2018.

14.

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ.

J Immunol. 2016 Dec 15;197(12):4829-4837. Epub 2016 Nov 2.

15.

Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.

Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M.

J Immunol. 2015 Feb 1;194(3):911-20. doi: 10.4049/jimmunol.1402346. Epub 2014 Dec 17.

16.

Novel antibodies against follicular non-Hodgkin's lymphoma.

van Meerten T, Hagenbeek A.

Best Pract Res Clin Haematol. 2011 Jun;24(2):231-56. doi: 10.1016/j.beha.2011.03.002. Epub 2011 May 5. Review.

PMID:
21658621
17.

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC.

Haematologica. 2010 Dec;95(12):2063-71. doi: 10.3324/haematol.2010.025783. Epub 2010 Sep 17.

18.

CD20-targeted therapy: the next generation of antibodies.

van Meerten T, Hagenbeek A.

Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007. Review.

PMID:
20350667
19.

CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.

van Meerten T, Hagenbeek A.

Neth J Med. 2009 Jul-Aug;67(7):251-9. Review.

20.

Influence of silicon on cobalt, zinc, and magnesium in baker's yeast, Saccharomyces cerevisiae.

Brasser HJ, Krijger GC, van Meerten TG, Wolterbeek HT.

Biol Trace Elem Res. 2006 Aug;112(2):175-89.

PMID:
17028383
21.

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.

van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB.

Clin Cancer Res. 2006 Jul 1;12(13):4027-35.

22.

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG.

J Immunol. 2006 Jul 1;177(1):362-71.

23.

Supplemental Content

Loading ...
Support Center